The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Ranibizumab in neovascular age-related macular degeneration
Open accessAbstract
Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“Their results are summarized below (Brown et al 2006; Rosenfeld et al 2006).”
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 3×
“Given as an intravitreal injection every 6 weeks, it has been shown to signifi cantly reduce visual loss in patients with CNV regardless of type or size (Gragoudas et al 2004).”
InfluentialPrevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
The splice variants of vascular endothelial growth factor (VEGF) and their receptors
Robinson, C. J., & Stringer, S. E. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.5.853 · Cited by 944
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
(2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.07.023 · Cited by 279
Cited by
Anand, S., Majeti, B. K., Acevedo, L. M., Murphy, E. A., Mukthavaram, R., Scheppke, L., Huang, M., Shields, D. J., Lindquist, J. N., Lapinski, P. E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2186 · Cited by 517
Keenan, T. D., & Chew, E. Y. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.2210 · Cited by 377
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Diabetic retinopathy and systemic vascular complications
Cheung, N., & Wong, T. Y. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.12.001 · Cited by 269
Sivaprasad, S., Hykin, P., Chakravarthy, U., Lotery, A., McKibbin, M., & Napier, J. (2016) · Clinical Ophthalmology · doi:10.2147/opth.s92627 · Cited by 31
Metadata
- Authors
- Eng, K. T., & Kertes, P. J.
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2006-12
- Volume
- 1
- Issue
- 4
- Pages
- 451-466
- ISSN
- 1176-9092 (ISSN-L)
- OpenAlex
- W2024548441
- Cited by
- 216
- References
- 8
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.